CA2893966C - Topical treatment of inflammatory skin conditions using a combination of aurin tricarboxylic, aurin quadracarboxylic and aurin hexacarboxylic acids - Google Patents
Topical treatment of inflammatory skin conditions using a combination of aurin tricarboxylic, aurin quadracarboxylic and aurin hexacarboxylic acids Download PDFInfo
- Publication number
- CA2893966C CA2893966C CA2893966A CA2893966A CA2893966C CA 2893966 C CA2893966 C CA 2893966C CA 2893966 A CA2893966 A CA 2893966A CA 2893966 A CA2893966 A CA 2893966A CA 2893966 C CA2893966 C CA 2893966C
- Authority
- CA
- Canada
- Prior art keywords
- use according
- condition
- aurin
- ata
- aha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 17
- -1 aurin hexacarboxylic acids Chemical class 0.000 title claims abstract description 12
- 241001060848 Carapidae Species 0.000 title claims abstract description 11
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 230000000699 topical effect Effects 0.000 title claims description 9
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims abstract description 44
- 201000004384 Alopecia Diseases 0.000 claims abstract description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 16
- 206010000496 acne Diseases 0.000 claims abstract description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 10
- 206010068168 androgenetic alopecia Diseases 0.000 claims abstract description 10
- 201000002996 androgenic alopecia Diseases 0.000 claims abstract description 10
- 208000001840 Dandruff Diseases 0.000 claims abstract description 8
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 8
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims abstract description 8
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 8
- 231100000360 alopecia Toxicity 0.000 claims abstract description 8
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 8
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 8
- 241000721454 Pemphigus Species 0.000 claims abstract description 7
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 7
- 208000004631 alopecia areata Diseases 0.000 claims abstract description 7
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 5
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims abstract description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 7
- 230000000172 allergic effect Effects 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 230000000475 sunscreen effect Effects 0.000 claims description 5
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- 241000195940 Bryophyta Species 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 235000011929 mousse Nutrition 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 5
- 206010053615 Thermal burn Diseases 0.000 abstract description 2
- 230000036575 thermal burns Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 30
- 210000004761 scalp Anatomy 0.000 description 17
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 16
- 102100035304 Lymphotactin Human genes 0.000 description 16
- 230000024203 complement activation Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000186892 Aloe vera Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010037884 Rash pruritic Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/694,484 | 2012-12-06 | ||
| US13/694,484 US8877808B2 (en) | 2012-12-06 | 2012-12-06 | Protection against skin diseases by aurin tricarboxylic acid and its derivatives |
| PCT/CA2013/050488 WO2014085920A1 (en) | 2012-12-06 | 2013-06-21 | Methods for preventing and treating inflammatory skin conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2893966A1 CA2893966A1 (en) | 2014-06-12 |
| CA2893966C true CA2893966C (en) | 2018-09-18 |
Family
ID=50881631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2893966A Active CA2893966C (en) | 2012-12-06 | 2013-06-21 | Topical treatment of inflammatory skin conditions using a combination of aurin tricarboxylic, aurin quadracarboxylic and aurin hexacarboxylic acids |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8877808B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2928460B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016501236A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150090920A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104902886A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2893966C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014085920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588879B2 (en) | 2011-08-01 | 2020-03-17 | Aurin Biotech Inc. | Treatment of age-related macular degeneration |
| ES2774776T3 (es) | 2013-11-18 | 2020-07-22 | Aurin Biotech Inc | Dímeros de ácido acetilsalicílico, síntesis de los mismos, y usos de los mismos para prevenir y tratar trastornos mediados por complemento |
| US11013750B2 (en) | 2017-01-20 | 2021-05-25 | Aurin Biotech Inc. | Methods for treating and preventing nociceptive pain |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4007270A (en) | 1975-11-18 | 1977-02-08 | American Cyanamid Company | Complement inhibitors |
| US5030442A (en) | 1987-03-30 | 1991-07-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition |
| DE4222534A1 (de) * | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| US5434185A (en) | 1993-05-17 | 1995-07-18 | The University Of Kentucky Research Foundation | Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts |
| US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| AU781151B2 (en) | 1999-10-26 | 2005-05-12 | Immusol Incorporated | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
| EP2000136A3 (en) * | 2000-02-28 | 2008-12-31 | The University of British Columbia | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| WO2010042728A1 (en) | 2008-10-08 | 2010-04-15 | Cornell University | Small molecule modulators of prongf uptake |
| US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
| US20130035392A1 (en) | 2011-08-01 | 2013-02-07 | Mcgeer Patrick L | Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
| JP2015522060A (ja) * | 2012-07-13 | 2015-08-03 | アウリン バイオテック インコーポレイテッド | アウリントリカルボン酸合成複合体の低分子量成分による、補体の膜侵襲複合体およびｃ３転換酵素の選択的阻害 |
-
2012
- 2012-12-06 US US13/694,484 patent/US8877808B2/en active Active
-
2013
- 2013-06-21 CA CA2893966A patent/CA2893966C/en active Active
- 2013-06-21 JP JP2015545609A patent/JP2016501236A/ja active Pending
- 2013-06-21 CN CN201380069919.XA patent/CN104902886A/zh active Pending
- 2013-06-21 WO PCT/CA2013/050488 patent/WO2014085920A1/en not_active Ceased
- 2013-06-21 EP EP13860898.9A patent/EP2928460B1/en not_active Not-in-force
- 2013-06-21 KR KR1020157017948A patent/KR20150090920A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014085920A1 (en) | 2014-06-12 |
| WO2014085920A9 (en) | 2015-05-21 |
| EP2928460A1 (en) | 2015-10-14 |
| EP2928460B1 (en) | 2017-12-27 |
| US20140163106A1 (en) | 2014-06-12 |
| US8877808B2 (en) | 2014-11-04 |
| CA2893966A1 (en) | 2014-06-12 |
| CN104902886A (zh) | 2015-09-09 |
| KR20150090920A (ko) | 2015-08-06 |
| EP2928460A4 (en) | 2016-08-17 |
| JP2016501236A (ja) | 2016-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5570992B2 (ja) | 皮膚病又は皮膚病変の治療方法及び組成物 | |
| JP6257518B2 (ja) | 皮膚剥脱のための組成物およびその使用 | |
| JP2012184253A (ja) | ざ瘡を治療するための組成物及び方法 | |
| CN111372595A (zh) | 治疗皮肤的方法和组合物 | |
| JP2010502700A (ja) | アクネを治療する医薬品、加齢および日焼けの症状を回復する医薬品、及び、これを用いた方法 | |
| US11090205B2 (en) | Methods and compositions for treatment of skin conditions | |
| KR20120118064A (ko) | 염증후 과다색소침착의 감소로 비코카서스인 모집단에서의 여드름 치료를 위한 아다팔렌과 벤조일 퍼옥사이드의 조합물을 포함하는 피부용 조성물 | |
| US20120258972A1 (en) | Composition and Methods for Treating Hair Loss | |
| CA2893966C (en) | Topical treatment of inflammatory skin conditions using a combination of aurin tricarboxylic, aurin quadracarboxylic and aurin hexacarboxylic acids | |
| US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| CN110769817A (zh) | 皮肤治疗方法、含类视黄醇的组合物及其递送系统 | |
| US20200030398A1 (en) | Skin care composition | |
| JP2016501236A5 (cg-RX-API-DMAC7.html) | ||
| CN111936130A (zh) | 包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 | |
| WO2016144196A1 (en) | A pharmaceutical and/or cosmetic composition for treating skin diseases and damages, the process for preparing of the pharmaceutical and/or cosmetic composition and its use | |
| WO2016033899A1 (zh) | 一种调节头皮油脂平衡的去屑组合物 | |
| AU2020282051B2 (en) | Composition containing fluoxetine and vitamin D 3 or its derivatives and application thereof | |
| US20040204492A1 (en) | Topical composition and method for treating seborrheic dermatitis | |
| KR20070000675A (ko) | 녹두 추출물, 백급 추출물 및 승마 추출물을 포함하는조성물 및 이의 용도 | |
| EP1688145A1 (en) | Methods and compositions for treating psoriasis | |
| Fathi et al. | Efficacy and Safety of Combination of Mometasone Furoate 0.1% Cream and Adapalene 0.1% Gel in Alopecia Areata | |
| JPH08337528A (ja) | メラニン生成抑制剤 | |
| SK9764Y1 (sk) | Prírodný dermálny krém na citlivú, ekzematickú a dermatóznu pokožku | |
| KR20040024213A (ko) | 홍삼 조사포닌을 함유하는 여드름 개선용 부직포 팩 | |
| ES2632591T3 (es) | Tratamiento de la seborrea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160622 |